CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Balance Sheet
USA - NASDAQ:CYCC - US23254L8019 - Common Stock
6.365 USD
-0.4 (-5.98%)
6.4 USD
+0.04 (+0.55%)
| MRQ (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | null | null | null | null | null | |||
| Cash Equivalents | 4.28M | 3.14M | 3.38M | 18.35M | 36.56M | |||
| Cash Due From Banks | null | null | null | null | null | |||
| Investments | null | null | null | null | null | |||
| Net Loans | null | null | null | null | null | |||
| Insurance Receivables | null | null | null | null | null | |||
| Marketable Securities | null | null | null | null | null | |||
| Receivables | null | 0 | 2.93M | 4.66M | 3.73M | |||
| Inventories | null | null | null | null | null | |||
| Other Current Assets | 108.00K | 537.00K | 1.13M | 1.41M | 660.00K | |||
| Total Current Assets | 4.38M | 3.67M | 7.44M | 24.41M | 40.94M | |||
| Non-Current Assets | ||||||||
| PPE Net | 18.00K | 8.00K | 102.00K | 170.00K | 90.00K | |||
| Investments And Advances | null | null | null | null | null | |||
| Goodwill | null | null | null | null | null | |||
| Intangibles | null | null | null | null | null | |||
| Other Non-Current Assets | 0 | 412.00K | 1.26M | 2.92M | 1.55M | |||
| Total Non-Current Assets | 18.00K | 420.00K | 1.36M | 3.09M | 1.65M | |||
| TOTAL ASSETS | 4.40M | 4.09M | 8.80M | 27.50M | 42.59M | |||
| LIABILITIES | ||||||||
| Total Deposits | null | null | null | null | null | |||
| Current Liabilities | ||||||||
| Short Term Borrowings | null | null | null | null | null | |||
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | |||
| Current Portion Of LT Debt. | null | null | null | null | null | |||
| Accrued Expenses | 501.00K | 1.39M | 4.24M | 3.94M | 2.54M | |||
| Accounts Payable | 221.00K | 4.60M | 3.54M | 2.56M | 2.12M | |||
| Other Current Liabilities | 38.00K | 283.00K | 380.00K | 890.00K | 630.00K | |||
| Total Current Liabilities | 760.00K | 6.27M | 8.16M | 7.39M | 5.29M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | |||
| Deferred Taxes/Income | null | null | null | null | null | |||
| Other Non-Current Liabilities | 10.00K | 0 | 37.00K | 110.00K | 30.00K | |||
| Total Non-Current Liabilities | 10.00K | 0 | 37.00K | 110.00K | 30.00K | |||
| TOTAL LIABILITIES | 770.00K | 6.27M | 8.20M | 7.50M | 5.32M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -441.78M | -439.49M | -428.28M | -406.16M | -384.96M | |||
| Additional Paid In Capital | 445.40M | 438.20M | 429.80M | 422.97M | 422.96M | |||
| Minority Interest | null | null | null | null | null | |||
| Common Shares | 5.00K | 9.00K | 1.00K | 4.50M | 10.00K | |||
| Treasury Stock | null | null | null | null | null | |||
| Other Shareholders' Equity | null | -891.00K | -908.00K | -1.32M | -750.00K | |||
| Shares Outstanding | 1.58M | 36.90K | 4.40K | 2.60K | 2.80K | |||
| Tangible Book Value per Share | 2.2904 | -58.9 | 137.6417 | 1.5949 | 3.7297 | |||
| Total Shareholders' Equity | 3.63M | -2.17M | 607.00K | 20.00M | 37.26M | |||
| TOTAL LIABILITIES AND EQUITY | 4.40M | 4.09M | 8.80M | 27.50M | 42.59M | |||
| Statistics | ||||||||
| Current Ratio | 5.77 | 0.59 | 0.91 | 3.30 | 7.74 | |||
| Return On Assets (ROA) | -146.06% | -273.86% | -258.44% | -77.82% | -44.82% | |||
| Return On Equity (ROE) | -177.03% | N/A | -3748.93% | -107.00% | -51.23% | |||
All data in USD , ROIC based on taxRate of 0.21